AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Energenesis Biomedical Co., Ltd. logo
Energenesis Biomedical Co., Ltd.Private
1 asset: 1 Ph 2ENERGI-F705Phase 2 · Parkinson's Disease1 Jan 2030ENERGI-F705 · Phase 2————
Enzychem Lifesciences logo
Enzychem Lifesciences183490 · KOSDAQ
1 asset: 1 Ph 2MosedipimodPhase 2 · Atopic DermatitisOct 2027Mosedipimod · Phase 2————
E
Essex Bio-Technology Limited1061 · HKEX
1 asset: 1 Ph 3HLX04-OPhase 3 · Age-Related Macular DegenerationPartial signalNone on record————
Everest Medicines (Beijing) Co., Ltd. logo
Everest Medicines (Beijing) Co., Ltd.1952 · HKEX
7 assets: 2 approved, 4 Ph 3, 1 Ph 2LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal26 Nov 2026MT1013 · Phase 3————
Faron Pharmaceuticals Ltd logo
Faron Pharmaceuticals LtdPrivate
1 asset: 1 Ph 2BexmarilimabPhase 2 · Higher-Risk Myelodysplastic SyndromesMar 2027Bexmarilimab · Phase 1/2—$14MDec 2025—$14M
Foresee Pharmaceuticals logo
Foresee Pharmaceuticals6576 · TPEx
1 asset: 1 Ph 2MirivadelgatPhase 2 · Pulmonary Hypertension Associated with Interstitial Lung DiseaseFeb 2028Mirivadelgat · Phase 2————
Formycon AG logo
Formycon AGFYB · Xetra
3 assets: 3 approvedApproved assets onlyNone on record—$81MDec 2025——
Fresenius Medical Care AG logo
Fresenius Medical Care AGFME · Xetra
1 asset: 1 approvedApproved assets onlyNone on record————
Fresenius SE & Co. KGaA logo
Fresenius SE & Co. KGaAFRE · Xetra
2 assets: 2 approvedApproved assets onlyNone on record—$5.0BJun 2026Profitable~$770M
Frontier Biotechnologies logo
Frontier Biotechnologies688221 · SSE STAR Market
2 assets: 1 Ph 3, 1 Ph 2AlbuvirtidePhase 3 · HIVPartial signalNone on record———$20M
F
Fuji Pharma Co., Ltd.4554.T · TSE
1 asset: 1 Ph 3ColestilanPhase 3 · Chronic Kidney DiseasePartial signalNone on record————
Galderma logo
GaldermaGALD · SIX
1 asset: 1 approvedApproved assets onlyDec 2026nemolizumab · Phase 2————
Galmed Pharmaceuticals Ltd. logo
Galmed Pharmaceuticals Ltd.EOCN · Nasdaq
1 asset: 1 Ph 3AramcholPhase 3 · MASH / NASHNone on record—$8.8MJun 2026~3.2 qtrs$5.6M
Gan & Lee Pharmaceuticals logo
Gan & Lee Pharmaceuticals603087 · SSE
4 assets: 2 Ph 3, 2 Ph 2BofanglutidePhase 3 · ObesityPartial signal2 Feb 2027GZR101 · Phase 1———$90M
GC Biopharma Corp. logo
GC Biopharma Corp.006280 · KOSPI
1 asset: 1 Ph 3Hepatitis B immune globulin (I.V.-Hepabig)Phase 3 · Chronic Hepatitis BNone on record————
Gedeon Richter logo
Gedeon RichterRICHT · Budapest Stock Exchange
2 assets: 2 approvedApproved assets only15 Dec 2026Cariprazine (Vraylar) · Phase 3————
GemVax & KAEL logo
GemVax & KAEL082270 · KOSDAQ
1 asset: 1 Ph 3TertomotidePhase 3 · Alzheimer's DiseasePartial signalNone on record—$15MMar 2026~7.6 qtrs~$5.6M
GEN Ilac ve Saglik Urunleri A.S. logo
GEN Ilac ve Saglik Urunleri A.S.Private
1 asset: 1 Ph 2SUL-238Phase 2 · Parkinson's DiseaseNone on record————
G
GEN İlaç ve Sağlık Ürünleri A.Ş.Private
1 asset: 1 Ph 2GN-037Phase 2 · PsoriasisNone on record————
Genenta Science S.p.A. logo
Genenta Science S.p.A.GNTA · Nasdaq
1 asset: 1 Ph 2TemferonPhase 1/2 · GlioblastomaNone on record—no price since 3 Nov 2026$33MDec 2025~17.0 qtrs$3.1M
Genentech (Roche Group) logo
Genentech (Roche Group)Private
1 asset: 1 approvedApproved assets only31 Mar 2028Risdiplam (Evrysdi) · Approved————
Genfit logo
GenfitGNFT · Euronext Paris
2 assets: 1 approved, 1 Ph 2EzurpimtrostatPhase 1/2 · Cholangiocarcinoma with KRAS Mutation17 Dec 2026Elafibranor · Phase 3—$119MDec 2025Ended Apr 2026$117M
GenFleet Therapeutics logo
GenFleet Therapeutics2595 · HKEX
3 assets: 1 Ph 3, 2 Ph 2GFH375Phase 3 · Non-Small Cell Lung Cancer30 Apr 2027GFH375 · Phase 2———$46M
Genovate Biotechnology logo
Genovate Biotechnology4130 · TPEx
2 assets: 2 Ph 3PrusogliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
Genrix Bio logo
Genrix Bio688443 · SSE STAR Market
3 assets: 2 Ph 3, 1 Ph 1Velinotamig (GR1803)Phase 3 · Multiple MyelomaWeak signal12 May 2027Velinotamig (GR1803) · Phase 2———$66M
GI Innovation, Inc. logo
GI Innovation, Inc.358570 · KOSDAQ
3 assets: 3 Ph 2Efdelikofusp alfaPhase 1/2 · Non-Small Cell Lung CancerFeb 2027GI-108 · Phase 1/2————
G
Glenmark Pharmaceuticals Ltd.GLENMARK · NSE
3 assets: 3 Ph 3AlmonertinibPhase 3 · Non-Small Cell Lung CancerPartial signalNov 2026Trastuzumab rezetecan · Phase 1/2————
GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025) logo
GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025)CBIO · Nasdaq
1 asset: 1 Ph 2CR-001Phase 1/2 · Solid TumorsFeb 2029CR-001 · Phase 1/2—$289MSep 2026~14.1 qtrs$177M
Grifols logo
GrifolsGRF · BME
3 assets: 1 approved, 1 Ph 3, 1 Ph 2Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3None on record—$970MDec 2025—$483M
Gubra logo
GubraGUBRA · Nasdaq Copenhagen
2 assets: 2 Ph 2BI 3034701Phase 2 · ObesityWeak signal15 Dec 2026BI 3034701 · Phase 1————
H. Lundbeck logo
H. LundbeckHLUN.B · Nasdaq Copenhagen
10 assets: 8 approved, 1 Ph 3, 1 Ph 2BexicaserinPhase 3 · EpilepsyPartial signal31 Dec 2026Bexicaserin · Phase 3————
Haisco Pharmaceutical Group logo
Haisco Pharmaceutical Group002653 · SZSE
8 assets: 5 Ph 3, 1 Ph 2, 2 Ph 1Anrikefon (HSK21542)Phase 3 · Chronic Kidney DiseaseReliable signal20 Dec 2026HSK47388 · Phase 2—$267MMar 2026—~$173M
Haleon US Holdings logo
Haleon US HoldingsPrivate
2 assets: 2 approvedApproved assets onlyNone on record————
HanAll BioPharma logo
HanAll BioPharma009420 · KOSPI
2 assets: 1 Ph 3, 1 Ph 1ImeroprubartPhase 3 · Myasthenia GravisMay 2027Imeroprubart · Phase 2————
Handok logo
Handok002390 · KOSPI
2 assets: 1 approved, 1 Ph 3TeneligliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
Hangzhou Zhongmei Huadong Pharmaceutical logo
Hangzhou Zhongmei Huadong Pharmaceutical000963 · SZSE
7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1janagliflozinPhase 3 · Type 2 DiabetesReliable signal1 Dec 2026HDM1005 · Phase 1———$244M
Hanmi Pharmaceutical logo
Hanmi Pharmaceutical128940 · KOSPI
5 assets: 1 Ph 3, 3 Ph 2, 1 Ph 1efpeglenatidePhase 3 · ObesityReliable signalJan 2027HM15275 · Phase 2———$161M
Hansa Biopharma logo
Hansa BiopharmaHNSA · Nasdaq Stockholm
1 asset: 1 Ph 3ImlifidasePhase 3 · Chronic Kidney DiseaseWeak signal28 Feb 2027Imlifidase · Phase 2—$71MMar 2026~3.3 qtrs~$27M
Hansoh Pharmaceutical Group logo
Hansoh Pharmaceutical Group3692 · HKEX
17 assets: 1 approved, 10 Ph 3, 3 Ph 2, 3 Ph 1olatorepatidePhase 3 · ObesityReliable signal25 Dec 2026HS-20118 · Phase 1—$4.5BDec 2025—$468M
Harbour BioMed logo
Harbour BioMed2142 · HKEX
2 assets: 1 Ph 3, 1 Ph 1WIN378Phase 2/3 · AsthmaWeak signal17 Dec 2027WIN378 · Phase 2————
Heartseed logo
Heartseed219A · TSE
1 asset: 1 Ph 2HS-001Phase 1/2 · Heart FailureNone on record—$40MMar 202610+ years—
H
Hebei Changshan Biochemical Pharmaceutical Co., Ltd300255 ·
1 asset: 1 Ph 3AlbenatidePhase 3 · Type 2 DiabetesPartial signalNone on record————
Heidelberg Pharma AG logo
Heidelberg Pharma AGHPHA · Xetra
1 asset: 1 Ph 2Pamlectabart tismanitinPhase 1/2 · Multiple MyelomaMar 2028Pamlectabart tismanitin · Phase 1/2—$38MMay 2025Ended Oct 2026~$29M
Hemostemix Inc. logo
Hemostemix Inc.HEM · TSXV
1 asset: 1 Ph 2ACP-01Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record————
Herantis Pharma Plc. logo
Herantis Pharma Plc.HRTIS ·
1 asset: 1 Ph 1HER-096Phase 1 · Parkinson's DiseasePartial signalNone on record————
HighTide Biopharma logo
HighTide Biopharma2511 · HKEX
1 asset: 1 Ph 3Berberine ursodeoxycholate (HTD1801)Phase 3 · Type 2 DiabetesReliable signalNone on record————
Hikma Pharmaceuticals PLC logo
Hikma Pharmaceuticals PLCHIK · LSE
3 assets: 3 approvedApproved assets only31 Jan 2027Cenobamate · Phase 2—$217MDec 2025Profitable$151M
HK inno.N Corporation logo
HK inno.N Corporation195940 · KOSDAQ
4 assets: 3 Ph 3, 1 Ph 2Amlodipine/valsartan/atorvastatin (CJ-30061)Phase 3 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record————
HLB Life Science logo
HLB Life Science067630 · KOSDAQ
2 assets: 2 Ph 3ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signalNov 2026Pyrotinib · Phase 1/2————
HLS Therapeutics Inc. logo
HLS Therapeutics Inc.HLS · TSX
2 assets: 2 approvedApproved assets onlyNone on record————
Hua Medicine logo
Hua Medicine2552 · HKEX
2 assets: 1 Ph 3, 1 Ph 1DorzagliatinPhase 3 · Type 2 DiabetesPartial signalNone on record—$156MDec 2025—$20M
H
Huadong Medicine000963 · SZSE
3 assets: 1 approved, 1 Ph 3, 1 Ph 2Edaravone (TTYP01)Phase 3 · Acute Ischemic StrokeMar 2028Pamlectabart tismanitin · Phase 1/2——Profitable—
Hubei Jumpcan Pharmaceutical logo
Hubei Jumpcan Pharmaceutical600566 · SSE
1 asset: 1 Ph 3EbronucimabPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signalNone on record————
Huons logo
Huons084110 · KOSDAQ
1 asset: 1 Ph 1Liraglutide (HUC2-676)Phase 1 · ObesityNone on record—$134MDec 2025—$47M
Hypera S.A. (Brainfarma Indústria Química e Farmacêutica S/A, wholly-owned subsidiary) logo
Hypera S.A. (Brainfarma Indústria Química e Farmacêutica S/A, wholly-owned subsidiary)HYPE3 · B3
2 assets: 1 approved, 1 otherDipyrone/Isometheptene mucate/Caffeine (Neosaldina)MigraineNone on record————
Idorsia Pharmaceuticals logo
Idorsia PharmaceuticalsIDIA · SIX
1 asset: 1 approvedApproved assets onlyNone on record—$119MMar 2026Ended Oct 2026$123M
IlDong Pharmaceutical Co., Ltd. logo
IlDong Pharmaceutical Co., Ltd.249420 · KOSPI
1 asset: 1 Ph 3Besifovir dipivoxil (Besivo)Phase 3 · Chronic Hepatitis BPartial signalNone on record————
Immuneering Corporation logo
Immuneering CorporationIMRX · Nasdaq
1 asset: 1 Ph 3AtebimetinibPhase 3 · Pancreatic CancerJun 2027Atebimetinib · Phase 1/2—$145MSep 2026~9.4 qtrs$55M
ImmuneOnco Biopharmaceuticals logo
ImmuneOnco Biopharmaceuticals1541 · HKEX
2 assets: 2 Ph 2Palverafusp alfaPhase 2 · Non-Small Cell Lung Cancer20 May 2027IMC-003 · Phase 1———~$46M
Immunocore Holdings plc logo
Immunocore Holdings plcIMCR · Nasdaq
2 assets: 1 approved, 1 Ph 3brenetafuspPhase 3 · Cutaneous Melanoma16 Oct 2027brenetafusp · Phase 3—$901MSep 202610+ years$289M
I
Imugene LimitedIMU · ASX
1 asset: 1 Ph 1Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis1 Dec 2026Azercabtagene zapreleucel · Phase 1————
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV · Nasdaq
3 assets: 3 approvedApproved assets onlyNone on record—no price since 2 Nov 2026$305MSep 2026Cash-flow positive$54M
Inmagene Biopharmaceuticals logo
Inmagene BiopharmaceuticalsIMA · Nasdaq
1 asset: 1 Ph 2OlevaprubartPhase 2 · Atopic DermatitisWeak signalDec 2027Olevaprubart · Phase 2—$127MSep 2026~13.9 qtrs$29M
Innate Pharma logo
Innate PharmaIPH · Euronext Paris
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signalApr 2028IPH4502 · Phase 1————
Innovent Biologics logo
Innovent Biologics1801 · HKEX
18 assets: 4 approved, 9 Ph 3, 3 Ph 2, 2 Ph 1IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal30 Nov 2026IBI363 · Phase 2—$2.6BDec 202510+ years$387M
Insilico Medicine logo
Insilico Medicine3696 · HKEX
1 asset: 1 Ph 2garutadustatPhase 2 · Ulcerative Colitis15 Aug 2027garutadustat · Phase 2—$393MDec 2025~4.5 qtrs$81M
International Stem Cell Corporation logo
International Stem Cell CorporationPrivate
1 asset: 1 Ph 1ISC-hpNSCPhase 1 · Parkinson's DiseaseWeak signalNone on record————
IntoCell, Inc logo
IntoCell, Inc287840 · KOSDAQ
1 asset: 1 Ph 1ITC-6146ROPhase 1 · Non-Small Cell Lung Cancer30 Jun 2027ITC-6146RO · Phase 1————
InventisBio logo
InventisBio688382 · SSE STAR Market
4 assets: 4 Ph 3BefotertinibPhase 3 · Non-Small Cell Lung CancerPartial signal21 Nov 2026Nomelcitinib (D-2570) · Phase 1—$173MJun 2026~17.3 qtrs~$54M
Ipsen logo
IpsenIPN · Euronext Paris
3 assets: 3 approvedApproved assets only17 Dec 2026Elafibranor · Phase 3————
IRLAB Therapeutics logo
IRLAB TherapeuticsIRLAB A · Nasdaq Stockholm
3 assets: 3 Ph 2Mesdopetam (IRL790)Phase 2 · Parkinson's DiseasePartial signalNone on record————
Jacobio Pharmaceuticals logo
Jacobio Pharmaceuticals1167 · HKEX
4 assets: 2 Ph 3, 2 Ph 2GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal31 Dec 2026JAB-23E73 · Phase 1/2—$149MJun 2025~18.4 qtrs~$26M
JCR Pharmaceuticals logo
JCR Pharmaceuticals4552 · TSE
3 assets: 2 approved, 1 Ph 3JR-131Phase 3 · Chronic Kidney DiseasePartial signalDec 2026Givinostat · Phase 2————
Jiangsu Hengrui Pharmaceuticals logo
Jiangsu Hengrui Pharmaceuticals600276 · SSE
116 assets: 45 Ph 3, 38 Ph 2, 26 Ph 1, 7 otherApatinibPhase 3 · Non-Small Cell Lung CancerReliable signalNov 2026HRS-1780 · Phase 2—$5.9BMar 2026—~$1.7B
Jiangsu Nhwa Pharmaceutical Co., Ltd. logo
Jiangsu Nhwa Pharmaceutical Co., Ltd.002262 · SZSE
2 assets: 1 Ph 2, 1 Ph 1NH102Phase 2 · Major Depressive DisorderPartial signalNone on record—$207MMar 2026—$92M
JW Pharmaceutical logo
JW Pharmaceutical001060 · KOSPI
7 assets: 5 Ph 3, 1 Ph 1, 1 otherAnagliptinPhase 3 · Type 2 DiabetesReliable signal31 Mar 2027Anagliptin · Approved———$48M
K
Kainos Medicine284620 · KOSDAQ
2 assets: 1 Ph 2, 1 Ph 1KM-819Phase 2 · Parkinson's DiseasePartial signalNone on record————
Kaken Pharmaceutical logo
Kaken Pharmaceutical4521 · TSE
2 assets: 1 approved, 1 Ph 3EnvudeucitinibPhase 3 · PsoriasisReliable signal1 Dec 2027Envudeucitinib · Phase 2————
Kamada logo
KamadaKMDA · Nasdaq
1 asset: 1 approvedApproved assets onlyNone on record—$75MDec 2025Cash-flow positive$13M
Kangstem Biotech logo
Kangstem Biotech217730 · KOSDAQ
1 asset: 1 Ph 2Furestem-CDPhase 1/2 · Crohn's DiseaseWeak signalNone on record————
Karyopharm Therapeutics logo
Karyopharm TherapeuticsKPTI · Nasdaq
2 assets: 1 approved, 1 Ph 2EltanexorPhase 1/2 · Multiple MyelomaWeak signalDec 2026Selinexor · Phase 2/3—no price since 10 Nov 2026$65MJun 2026~4.0 qtrs$121M
Keenova Therapeutics logo
Keenova TherapeuticsPrivate
4 assets: 4 approvedApproved assets onlyNone on record—$813MDec 2025Ended May 2026~$177M
Keymed Biosciences logo
Keymed Biosciences2162 · HKEX
6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1stapokibartPhase 3 · Atopic DermatitisReliable signalDec 2026Gamgertamig (CM336) · Phase 1/2—$280MDec 2025~3.8 qtrs$100M
K
Kiniksa PharmaceuticalsKNSA · Nasdaq
1 asset: 1 Ph 2vixarelimabPhase 2 · Ulcerative ColitisPartial signal25 Aug 2027vixarelimab · Phase 2—$569MSep 2026Cash-flow positive$136M
Kissei Pharmaceutical logo
Kissei Pharmaceutical4547 · TSE
7 assets: 3 approved, 3 Ph 3, 1 Ph 2OmarigliptinPhase 3Reliable signal30 Apr 2027Olutasidenib · Approved—$330MMar 2026—$148M
K
Knight TherapeuticsGUD · TSX
6 assets: 6 approvedApproved assets onlyDec 2026viloxazine · Phase 3————
Korea United Pharm logo
Korea United Pharm033270 · KOSPI
2 assets: 1 Ph 3, 1 Ph 1Cilostazol/rosuvastatin (UI022/UI023)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signalNone on record————
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS ·
4 assets: 1 approved, 1 Ph 2, 2 Ph 1KB707Phase 1/2 · Non-Small Cell Lung CancerDec 2026KB407 · Phase 1—$912MSep 2026Cash-flow positive$60M
Kureha Corporation logo
Kureha Corporation4023 · TSE
1 asset: 1 Ph 3AST-120Phase 3 · Chronic Kidney DiseasePartial signalNone on record————
K
Kwang Dong Pharmaceutical009290 · KOSPI
1 asset: 1 Ph 2bremelanotidePhase 2 · ObesityReliable signalNone on record—$98MDec 2025—$6.4M
Kyowa Kirin logo
Kyowa Kirin4151 · TSE
9 assets: 6 approved, 3 Ph 1KK2269Phase 1 · Non-Small Cell Lung CancerDec 2026Ziftomenib · Phase 1—$1.4BDec 2025—$676M
Laboratorios Farmacéuticos Rovi, S.A. logo
Laboratorios Farmacéuticos Rovi, S.A.ROVI · BME
1 asset: 1 Ph 1Risperidone (QUAR)Phase 1 · SchizophreniaWeak signalNone on record————
Laekna Limited logo
Laekna Limited2105 · HKEX
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal30 Jun 2027LAE102 · Phase 1—$165MJun 202610+ years~$28M
Lee's Pharmaceutical logo
Lee's Pharmaceutical0950 · HKEX
4 assets: 2 Ph 3, 1 Ph 2, 1 otherLoxapine (Adasuve)Phase 3 · SchizophreniaReliable signalDec 2028Istaroxime · Phase 2/3—$45MDec 2025—$14M
LG Chem logo
LG Chem051910 · KOSPI
4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1GemigliptinPhase 3 · Type 2 DiabetesReliable signalNov 2027LB-LR1109 · Phase 1————
Lifeward Ltd. logo
Lifeward Ltd.LFWD · Nasdaq
1 asset: 1 Ph 3ORMD-0801Phase 3 · Type 2 DiabetesPartial signalNone on record—$5.0MSep 2026~1.0 qtrs$10M
LigaChem Biosciences, Inc. logo
LigaChem Biosciences, Inc.141080 · KOSDAQ
2 assets: 1 Ph 2, 1 Ph 1LCB84Phase 1/2 · Non-Small Cell Lung CancerJan 2027LCB84 · Phase 1/2————
L
Livzon Pharmaceutical Group Inc.000513 · SZSE
1 asset: 1 Ph 3LecankitugPhase 3 · PsoriasisNone on record——Profitable—
Lundbeck LLC logo
Lundbeck LLCPrivate
2 assets: 2 approvedApproved assets onlyNone on record————
Lupin Limited logo
Lupin LimitedLUPIN · NSE
3 assets: 2 approved, 1 Ph 3BofanglutidePhase 3 · ObesityPartial signal30 Jun 2027Bofanglutide · Phase 3——Profitable$233M

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415